Evommune stock slides 13% after EVO756 fails Phase 2b atopic dermatitis trial

Evommune's stock dropped 13.9% in pre-market trading to $11.26 following Tuesday evening's announcement that EVO756, its experimental therapy for moderate-to-severe atopic dermatitis, missed both primary and secondary efficacy endpoints across all evaluated doses in a Phase 2b study. The randomized, double-blind, placebo-controlled trial enrolled 121 adults over 12 weeks; the primary endpoint, percent change from baseline in the Eczema Area and Severity Index score at Week 12, was not achieved. The company has decided not to move EVO756 forward into further atopic dermatitis studies, but it will continue a separate Phase 2b program examining the drug for migraine prophylaxis.

This decline is especially significant because the atopic dermatitis failure represents EVO756's second consecutive Phase 2b disappointment in 2026. Earlier this year, the drug missed its primary endpoint in a chronic spontaneous urticaria trial, leading the company to terminate that indication entirely and prompting William Blair to downgrade the stock to Market Perform. A pattern of insider stock sales by senior executives during the months surrounding these setbacks has further undermined investor confidence. Evercore ISI maintained its Buy rating on the stock today, although the broader analyst community remains divided on the company's prospects.

With the two most advanced near-term indications for EVO756 now halted, Evommune's pipeline value increasingly rests on EVO301, an IL-18 binding protein fusion candidate in Phase 2b development for atopic dermatitis and ulcerative colitis, as well as the newly initiated migraine prophylaxis study. The broader U.S. equity market provided no cushion, as the S&P 500, Dow Jones, and Nasdaq all traded lower in pre-market action, reflecting cautious macroeconomic sentiment.

The combination of a binary clinical miss in a closely watched indication, the precedent set by the earlier chronic spontaneous urticaria setback, and a risk-off market environment amplified the pressure on EVMN shares, driving them toward their 52-week low of $10.47 — far below the 52-week high of $33.20 — and underscoring how much of the company's valuation had been tied to EVO756's potential in inflammatory skin disease.

This piece was produced with the aid of artificial intelligence and subsequently reviewed by an editor. For full details, please refer to the site's terms and conditions.